Management of Adverse Events during Treatment of Tuberculosis in the Patient with Systemic Lupus Erythematosus
M. I. Romanova,
E. V. Vaniev,
D. O. Churkin,
A. V. Abramchenko,
A. I. Gayda,
O. V. Lovacheva,
A. G. Samoylova https://doi.org/10.58838/2075-1230-2023-101-4-80-86
Abstract
The article describes a clinical case of chemotherapy for drug susceptible rapidly progressive pulmonary tuberculosis in a patient with systemic lupus erythematosus taking glucocorticosteroids on regular basis. Due to adverse events that occurred when using the regimen of first line drugs, the patient discontinued taking first line drugs and was immediately switched to second line drugs. A timely decision to completely cancel the chemotherapy regimen with first line drugs that caused AE, the immediate start of the individual regimen (Bq, Lzd, Lfx, and Tzd) made it possible to cure pulmonary and bronchial tuberculosis in this patient. At the same time, data were obtained on the effective and safe use of tuberculosis treatment regimen (Bq, Lzd, Lfx, and Tzd) while taking GCS for SLE.
About the Authors
M. I. Romanova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Maria I. Romanova - Junior Researcher.
4, Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
E. V. Vaniev
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Eduard V. Vaniev - Candidate of Medical Sciences, Head of Therapy Department no. 2.
4, Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
D. O. Churkin
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Denis O. Churkin – Phthisiologist.
4, Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
A. V. Abramchenko
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Anna V. Abramchenko - Associate Professor of Phthisiology Department, Junior Researcher of Research Department for Differential Diagnostics and Treatment of Tuberculosis and Concurrent Infections, National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health.
4, Dostoevsky St., Moscow, 127473; 1, Ostrovityanova St., Moscow, 117997
Phone: +7 (495) 681-11-66; +7 (495) 434-22-66
A. I. Gayda
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasia I. Gayda - Candidate of Medical Sciences, Junior Researcher.
4, Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
O. V. Lovacheva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Olga V. Lovacheva - Doctor of Medical Sciences, Professor, Chief Researcher of Research Department for Differential Diagnostics and Treatment of Tuberculosis and Concurrent Infections.
4, Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasia G. Samoylova - Doctor of Medical Sciences, Deputy Director for Research.
4, Dostoevsky St., Moscow, 127473
Phone: +7 (495) 681-11-66
References
1. Klyukvina N. G. The problem of comorbidity in systemic lupus erythematosus. RMJ, 2015, no. 7, pp. 370. (In Russ.)
2. de Luis A., Pigrau C., Pahissa A., Fernández F., Martínez-Vázquez J. M. Infecciones en 96 casos de lupus eritematoso sistémico. Med. Clin (Barc), 1990, vol. 95, no. 1, pp. 24. PMID: 2381245.
3. Falagas M. E., Voidonikola P. T., Angelousi A. G. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int. J. Antimicrob. Agents, 2007, vol. 30, no. 6, pp. 477-486. https://doi.org/10.1016/j.ijantimicag.2007.07.010
4. Janwityanuchit S., Totemchokchyakarn K., Krachangwongchai K., Vatanasuk M. Infection in systemic lupus erythematosus. J. Med. Assoc. Thai., 1993, vol. 76, no. 10, pp. 542-548. PMID: 7964223.
5. Jick S. S., Lieberman E. S., Rahman M. U., Choi H. K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis. Rheum., 2006, vol. 55, no. 1, pp. 19-26.
6. Malaviya A. N., Chandraseka ran A. N., Kumar A., Shamar P. N. Systemic lupus erythematosus in India. Lupus, 1997, vol. 6, no. 9, pp. 690-700. https://doi.org/10.1177/096120339700600903
7. Nossent J., Cikes N., Kiss E., Marchesoni A., Nassonova V., Mosca M., Olesinska M., Pokorny G., Rozman B., Schneider M., Vlachoyiannopoulos P. G., Swaak A. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus, 2007, vol. 16, no. 5, pp. 309-317. https://doi.org/10.1177/0961203307077987
8. Sayarlioglu M., Inanc M., Kamali S., Cefle A., Karaman O., Gul A., Ocal L., Aral O., Konice M. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus, 2004, vol. 13, no. 4, pp. 274-278. https://doi.org/10.1191/0961203303lu529xx
9. Steiger S., Ehreiser L., Anders J., Anders H. J. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. Front. Immunol., 2022, no. 13, pp. 999704. https://doi.org/10.3389/fimmu.2022.999704
10. Tam L. S., Li E. K., Wong S. M., Szeto C. C. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand. J. Rheumatol., 2002, no. 31, pp. 296-300.
11. Zucchi D., Elefante E., Schiliro D., Signorini V., Trentin F., Bortoluzzi A., Tani C. One year in review 2022: systemic lupus erythematosus. Clin. Exp. Rheumatol., 2022, vol. 40, no. 1, pp. 4-14. https://doi.org/10.55563/clinexprheumatol/nolysy
Review
For citations:
Romanova M.I., Vaniev E.V., Churkin D.O., Abramchenko A.V., Gayda A.I., Lovacheva O.V., Samoylova A.G. Management of Adverse Events during Treatment of Tuberculosis in the Patient with Systemic Lupus Erythematosus. Tuberculosis and Lung Diseases. 2023;101(4):80-86. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-4-80-86
Views:
594
Email this article 